Published in Clin J Am Soc Nephrol on December 05, 2013
Chronic Kidney Disease in Children Prospective Cohort Study (CKiD) (CKiD) | NCT00327860
Primary osteoblast-like cells from patients with end-stage kidney disease reflect gene expression, proliferation, and mineralization characteristics ex vivo. Kidney Int (2014) 1.65
Fracture Burden and Risk Factors in Childhood CKD: Results from the CKiD Cohort Study. J Am Soc Nephrol (2015) 1.47
Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int (2016) 0.95
The use of fibroblast growth factor 23 testing in patients with kidney disease. Clin J Am Soc Nephrol (2014) 0.86
Endocrine FGFs: Evolution, Physiology, Pathophysiology, and Pharmacotherapy. Front Endocrinol (Lausanne) (2015) 0.83
Deregulated Renal Calcium and Phosphate Transport during Experimental Kidney Failure. PLoS One (2015) 0.80
Prevalence and correlates of 25-hydroxyvitamin D deficiency in the Chronic Kidney Disease in Children (CKiD) cohort. Pediatr Nephrol (2015) 0.80
Fibroblast Growth Factor 23 and Risk of CKD Progression in Children. Clin J Am Soc Nephrol (2016) 0.80
Mineral metabolism in European children living with a renal transplant: a European society for paediatric nephrology/european renal association-European dialysis and transplant association registry study. Clin J Am Soc Nephrol (2015) 0.79
Characterization of FGF23-Dependent Egr-1 Cistrome in the Mouse Renal Proximal Tubule. PLoS One (2015) 0.78
The role of bone in CKD-mediated mineral and vascular disease. Pediatr Nephrol (2014) 0.78
Proteinuria Increases Plasma Phosphate by Altering Its Tubular Handling. J Am Soc Nephrol (2014) 0.78
Extrarenal effects of FGF23. Pediatr Nephrol (2016) 0.78
The Kidney-Vascular-Bone Axis in the Chronic Kidney Disease-Mineral Bone Disorder. Transplantation (2016) 0.78
Fibroblast growth factor 23 and acute kidney injury. Pediatr Nephrol (2014) 0.77
Relationship of FGF23 to indexed left ventricular mass in children with non-dialysis stages of chronic kidney disease. Pediatr Nephrol (2015) 0.77
Altered Osteocyte-Specific Protein Expression in Bone after Childhood Solid Organ Transplantation. PLoS One (2015) 0.76
Effects of dietary iron intake and chronic kidney disease on fibroblast growth factor 23 metabolism in wild-type and hepcidin knockout mice. Am J Physiol Renal Physiol (2016) 0.75
Cardiovascular Disease Risk Factors and Left Ventricular Hypertrophy in Girls and Boys With CKD. Clin J Am Soc Nephrol (2016) 0.75
Klotho modulates FGF23-mediated NO synthesis and oxidative stress in human coronary artery endothelial cells. Pflugers Arch (2016) 0.75
Treatment of Pediatric Chronic Kidney Disease-Mineral and Bone Disorder. Curr Osteoporos Rep (2017) 0.75
Klotho/FGF23 Axis in Chronic Kidney Disease and Cardiovascular Disease. Kidney Dis (Basel) (2016) 0.75
Exhaled volatile substances mirror clinical conditions in pediatric chronic kidney disease. PLoS One (2017) 0.75
The FGF23-Klotho axis and cardiac tissue Doppler imaging in pediatric chronic kidney disease-a prospective cohort study. Pediatr Nephrol (2017) 0.75
K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis (2003) 16.18
A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics (1976) 13.83
Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med (2008) 9.19
FGF23 induces left ventricular hypertrophy. J Clin Invest (2011) 7.22
Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int (2006) 7.02
Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest (2004) 7.00
FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res (2003) 6.81
Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA (2011) 5.86
Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol (2005) 5.76
Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation (2009) 4.87
Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int (2011) 4.74
Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol (2007) 4.59
Long-term survival of children with end-stage renal disease. N Engl J Med (2004) 4.10
Design and methods of the Chronic Kidney Disease in Children (CKiD) prospective cohort study. Clin J Am Soc Nephrol (2006) 3.84
Prevalence and associations of 25-hydroxyvitamin D deficiency in US children: NHANES 2001-2004. Pediatrics (2009) 3.62
Glomerular filtration rate via plasma iohexol disappearance: pilot study for chronic kidney disease in children. Kidney Int (2006) 3.48
Prevalence of vitamin D deficiency among healthy infants and toddlers. Arch Pediatr Adolesc Med (2008) 3.44
Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int (2010) 3.04
Analytical and clinical validation of the 25 OH vitamin D assay for the LIAISON automated analyzer. Clin Biochem (2004) 2.78
An evaluation of automated methods for measurement of serum 25-hydroxyvitamin D. Clin Biochem (2009) 2.41
Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production. J Biol Chem (2002) 2.12
Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. Bone (2009) 2.00
Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Am J Physiol Renal Physiol (2007) 1.95
Improved equations estimating GFR in children with chronic kidney disease using an immunonephelometric determination of cystatin C. Kidney Int (2012) 1.93
Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis (2004) 1.93
Patients with autosomal dominant polycystic kidney disease have elevated fibroblast growth factor 23 levels and a renal leak of phosphate. Kidney Int (2010) 1.77
Quantification of circulating 1,25-dihydroxyvitamin D by radioimmunoassay with 125I-labeled tracer. Clin Chem (1996) 1.76
Vitamin D insufficiency and hyperparathyroidism in children with chronic kidney disease. Pediatr Nephrol (2008) 1.63
Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J Clin Endocrinol Metab (1988) 1.46
Investigating FGF-23 concentrations and its relationship with declining renal function in paediatric patients with pre-dialysis CKD Stages 3-5. Nephrol Dial Transplant (2012) 1.45
The influence of glomerular filtration rate and age on fibroblast growth factor 23 serum levels in pediatric chronic kidney disease. J Clin Endocrinol Metab (2010) 1.42
Mineral metabolites and CKD progression in African Americans. J Am Soc Nephrol (2012) 1.41
Metabolic abnormalities, cardiovascular disease risk factors, and GFR decline in children with chronic kidney disease. Clin J Am Soc Nephrol (2011) 1.34
Early skeletal and biochemical alterations in pediatric chronic kidney disease. Clin J Am Soc Nephrol (2011) 1.25
Role of Klotho in aging, phosphate metabolism, and CKD. Am J Kidney Dis (2011) 1.15
FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy. Clin J Am Soc Nephrol (2012) 1.09
Fibroblast growth factor 23 and soluble klotho in children with chronic kidney disease. Nephrol Dial Transplant (2012) 1.02
Paediatric reference values for the C-terminal fragment of fibroblast-growth factor-23, sclerostin, bone-specific alkaline phosphatase and isoform 5b of tartrate-resistant acid phosphatase. Ann Clin Biochem (2012) 1.02
Fibroblast growth factor 23 and bone metabolism in children with chronic kidney disease. Kidney Int (2010) 0.98
Age- and sex-specific pediatric reference intervals and correlations for zinc, copper, selenium, iron, vitamins A and E, and related proteins. Clin Chem (1988) 0.94
Vitamin D insufficiency and effect of cholecalciferol in children with chronic kidney disease. Pediatr Nephrol (2010) 0.92
Vitamin D deficiency and parathyroid hormone levels following renal transplantation in children. Pediatr Nephrol (2010) 0.89
Serum osteoprotegerin, RANKL and fibroblast growth factor-23 in children with chronic kidney disease. Pediatr Nephrol (2011) 0.87
Vitamin D deficiency is common in children and adolescents with chronic kidney disease. Kidney Int (2011) 0.87
Reduced plasma concentration of 1,25-dihydroxyvitamin D in children with moderate renal insufficiency. Kidney Int (1982) 0.81
Altered divalent ion metabolism in early renal failure: role of 1,25(OH)2D. Kidney Int (1985) 0.77
Vitamin D deficiency and risk of cardiovascular disease. Circulation (2008) 13.39
New equations to estimate GFR in children with CKD. J Am Soc Nephrol (2009) 11.48
Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med (2008) 9.19
Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet (2010) 8.89
Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med (2003) 8.87
FGF23 induces left ventricular hypertrophy. J Clin Invest (2011) 7.22
Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med (2003) 6.41
Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA (2011) 5.86
Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol (2005) 5.76
Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med (2007) 5.26
Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation (2009) 4.87
Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int (2011) 4.74
DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet (2006) 4.49
Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol (2005) 4.44
Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology (2004) 3.89
Design and methods of the Chronic Kidney Disease in Children (CKiD) prospective cohort study. Clin J Am Soc Nephrol (2006) 3.84
Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int (2003) 3.75
Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res (2006) 3.66
A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease. Kidney Int (2009) 3.41
Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol (2008) 3.26
Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol (2004) 3.23
Improvement in outcomes of clinical islet transplantation: 1999-2010. Diabetes Care (2012) 3.20
National Kidney Foundation's Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. Pediatrics (2003) 3.10
Genetic variants and associations of 25-hydroxyvitamin D concentrations with major clinical outcomes. JAMA (2012) 3.10
Calciphylaxis from nonuremic causes: a systematic review. Clin J Am Soc Nephrol (2008) 3.00
Effects of phosphate binders in moderate CKD. J Am Soc Nephrol (2012) 2.92
Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA (2012) 2.85
Blood pressure in children with chronic kidney disease: a report from the Chronic Kidney Disease in Children study. Hypertension (2008) 2.84
A novel method for the assessment of cellular composition and beta-cell viability in human islet preparations. Am J Transplant (2005) 2.74
Adiposity, cardiometabolic risk, and vitamin D status: the Framingham Heart Study. Diabetes (2009) 2.70
Hepcidin--a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol (2009) 2.61
Diuretics, calciuria and secondary hyperparathyroidism in the Chronic Renal Insufficiency Cohort. Nephrol Dial Transplant (2011) 2.60
Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med (2010) 2.55
Chronic kidney disease, hypovitaminosis D, and mortality in the United States. Kidney Int (2009) 2.52
HIV transmission risk behaviors among HIV-infected persons who are successfully linked to care. Clin Infect Dis (2008) 2.44
Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int (2010) 2.31
Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res (2011) 2.30
Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol Dial Transplant (2010) 2.23
A mutant PTH/PTHrP type I receptor in enchondromatosis. Nat Genet (2002) 2.19
Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab (2009) 2.12
First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab (2004) 2.11
Ollier disease. Orphanet J Rare Dis (2006) 2.11
Association of serum bicarbonate with risk of renal and cardiovascular outcomes in CKD: a report from the Chronic Renal Insufficiency Cohort (CRIC) study. Am J Kidney Dis (2013) 2.09
Elevated blood pressure and decreased cognitive function among school-age children and adolescents in the United States. J Pediatr (2003) 2.07
Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. Bone (2009) 2.00
Echo-Doppler assessment of the biophysical properties of the aorta in children with chronic kidney disease. Pediatr Cardiol (2013) 1.98
Association of proteinuria with race, cause of chronic kidney disease, and glomerular filtration rate in the chronic kidney disease in children study. Clin J Am Soc Nephrol (2009) 1.98
Glomerular filtration rate measurement and estimation in chronic kidney disease. Pediatr Nephrol (2007) 1.93
Improved equations estimating GFR in children with chronic kidney disease using an immunonephelometric determination of cystatin C. Kidney Int (2012) 1.93
The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects. Transplantation (2008) 1.83
A novel missense mutation in SLC34A3 that causes hereditary hypophosphatemic rickets with hypercalciuria in humans identifies threonine 137 as an important determinant of sodium-phosphate cotransport in NaPi-IIc. Am J Physiol Renal Physiol (2008) 1.81
Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol (2013) 1.78
Parathyroid hormone and parathyroid hormone-related peptide, and their receptors. Biochem Biophys Res Commun (2005) 1.78
Autosomal dominant pseudohypoparathyroidism type Ib is associated with a heterozygous microdeletion that likely disrupts a putative imprinting control element of GNAS. J Clin Invest (2003) 1.77
Value of the new bone classification system in pediatric renal osteodystrophy. Clin J Am Soc Nephrol (2010) 1.75
Effects of frequent hemodialysis on measures of CKD mineral and bone disorder. J Am Soc Nephrol (2012) 1.75
First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl. Kidney Int (2005) 1.74
First-trimester sex hormone binding globulin and subsequent gestational diabetes mellitus. Am J Obstet Gynecol (2003) 1.73
Postpartum diabetes screening in women with a history of gestational diabetes. Obstet Gynecol (2005) 1.70
Critical role of parathyroid hormone (PTH) receptor-1 phosphorylation in regulating acute responses to PTH. Proc Natl Acad Sci U S A (2013) 1.68
Deletion of the NESP55 differentially methylated region causes loss of maternal GNAS imprints and pseudohypoparathyroidism type Ib. Nat Genet (2004) 1.68
A novel COL1A1 mutation in infantile cortical hyperostosis (Caffey disease) expands the spectrum of collagen-related disorders. J Clin Invest (2005) 1.68
Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab (2008) 1.67
Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int (2013) 1.66
Long-term insulin independence and improvement in insulin secretion after supplemental islet infusion under exenatide and etanercept. Transplantation (2008) 1.66
FGF-23: More than a regulator of renal phosphate handling? J Bone Miner Res (2010) 1.63
Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD. J Am Soc Nephrol (2008) 1.60
The association between intrauterine growth restriction in the full-term infant and high blood pressure at age 7 years: results from the Collaborative Perinatal Project. Int J Epidemiol (2006) 1.60
Hemoglobin differences by race in children with CKD. Am J Kidney Dis (2010) 1.60
Adaptation to metabolic acidosis and its recovery are associated with changes in anion exchanger distribution and expression in the cortical collecting duct. Kidney Int (2010) 1.58
Extracellular volume and glomerular filtration rate in children with chronic kidney disease. Clin J Am Soc Nephrol (2011) 1.57
Mineral abnormalities and long-term graft function in pediatric renal transplant recipients: a role for FGF-23? Nephrol Dial Transplant (2011) 1.57
Agonistic angiotensin II type 1 receptor autoantibodies in postpartum women with a history of preeclampsia. Hypertension (2007) 1.56
Genomic imbalances in pediatric patients with chronic kidney disease. J Clin Invest (2015) 1.56
Dosage-dependent switch from G protein-coupled to G protein-independent signaling by a GPCR. EMBO J (2006) 1.56
GNAS locus and pseudohypoparathyroidism. Horm Res (2005) 1.56
Health-related quality of life of children with mild to moderate chronic kidney disease. Pediatrics (2010) 1.52
Reliability of resting blood pressure measurement and classification using an oscillometric device in children with chronic kidney disease. J Pediatr (2011) 1.51